Fig. 3From: Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysisForest plots of treatment for PFS and adverse events. A PFS in the overall population with ovarian cancer, B PFS for women with BRCAm, C PFS for women with HRD, D Adverse events in all populations. BRCAm, BRCA1/2 mutation; CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficiencyBack to article page